Polycythemia Vera malady

NIH Rare Diseases: Polycythemia vera is a condition characterized by an increased number of red blood cells within the bloodstream. Affected individuals may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain. Polycythemia vera is associated with mutations in the JAK2 and TET2 genes. Most cases are not inherited, as the condition is associated with genetic changes that are somatic, which means they are acquired during a person's lifetime and are present only in certain cells.³⁰

MalaCards: Polycythemia Vera, also known as prv, is related to essential thrombocythemia and myelofibrosis. An important gene associated with Polycythemia Vera is CD177 (CD177 molecule), and among its related pathways are Jak/Stat Pathway and Immune response Oncostatin M signaling via JAK-Stat in human cells. The drugs anagrelide and anagrelide hydrochloride and the compounds cyclophosphamide and threonine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, brain and heart, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Genetics Home Reference: Polycythemia vera is a condition characterized by an increased number of red blood cells within the bloodstream. Affected individuals may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain.¹⁷

Wikipedia: Polycythemia vera (PV, PCV) (also known as erythremia, primary polycythemia and polycythemia rubra vera)...⁴⁴ more...

OMIM: 263300

Aliases & Descriptions:

polycythemia vera 6 7 30 17 8 33 32 43 prv 30 17 pv 30 17 erythremia (morphologic abnormality) 6 proliferative polycythaemia 6

polycythaemia rubra vera 6 polycythemia rubra vera 30 osler-vaquez syndrome 6 primary polycythemia 17 osler-vaquez disease 17

Diseases related to polycythemia vera by text searches and GeneDecks gene sharing:

(show top 50)    (show all 774)

id	Related Disease	Score	Top Affiliating Genes
1	essential thrombocythemia	39.0	MPL, JAK2, THPO
2	myelofibrosis	37.4	JAK2, CD177, HMGA2, THPO, EPO
3	primary polycythemia	34.0	SOCS2, SOCS3, EPO, EPOR
4	erythrocytosis	32.9	KITLG, SELP, BCL2L1, MPL, JAK2, CD177
5	splenomegaly	30.4	MPL, JAK2, ITGB2, IFNA1, IFNA2, TET2
6	myeloproliferative disorder	29.6	KIT, KITLG, VWF, SELP, BCR, MPL
7	thrombocytosis	29.1	KITLG, VWF, SELP, SERPINC1, MPL, JAK1
8	chronic myeloproliferative disease	28.6	MPL, MPO, JAK2, CD177, FLT3, IL6
9	heparin-induced thrombocytopenia	28.5	SELP, SERPINC1, SERPINE1, CD79A, ITGA2, ITGB3
10	thromboembolism	28.3	VWF, SELP, SERPINC1, SERPINE1, ITGA2, F5
11	venous thrombosis	28.0	VWF, SELP, SERPINC1, SERPINE1, JAK2, ITGAM
12	portal vein thrombosis	28.0	SELP, SERPINC1, SERPINE1, JAK2, IFNA1, IFNA2
13	hemochromatosis	27.6	MPO, IL6, IGF1, F5, F2, ACE
14	thrombophilia	26.8	VWF, SELP, SERPINC1, SERPINE1, JAK2, ITGB3
15	pemphigus	26.2	CD79A, IL6, IFNA1, IFNA2, HLA-G, SRC
16	stomatitis	25.8	PIK3CG, BCL2L1, CD79A, IL11, IL6, IFNA1
17	prostate cancer, progression of	25.6	SERPINE1, BCL2L1, CDKN3, ITGA2, IL6, IGF1R
18	thrombosis	25.4	PIK3CG, VWF, SELP, SERPINC1, SERPINE1, MPL
19	disseminated intravascular coagulation	25.1	VWF, SERPINC1, SERPINE1, MPO, IL11, IL6
20	hematopoiesis	24.6	PIK3CG, KIT, KITLG, BOK, BCL2L1, BCR
21	squamous cell carcinoma	24.6	RARB, KDM4C, BCL2L1, ITGA2, ITGB2, FAM215A
22	polycythemia	24.2	PICALM, PIK3CG, KIT, KITLG, VWF, SELP
23	thrombocytopenia	24.1	KITLG, VWF, SELP, SERPINC1, SERPINE1, MPL
24	glomerulonephritis	23.5	KIT, KITLG, VWF, SELP, SERPINC1, SERPINE1
25	acute myeloid leukemia	21.5	PICALM, PIK3CG, KIT, KITLG, VWF, BOK
26	anemia	20.9	KIT, KITLG, VWF, SELP, SERPINC1, RARB
27	myeloid leukemia	20.7	PICALM, PIK3CG, KIT, KITLG, VWF, SELP
28	coronary heart disease	20.4	VWF, SELP, SERPINC1, SERPINE1, MPO, CD79A
29	hypertension	19.8	PIK3CG, KIT, VWF, SELP, SERPINC1, SERPINE1
30	cervical cancer	19.6	PIK3CG, SERPINC1, SERPINE1, RARB, BCL2L1, MPO
31	neuroblastoma	19.1	PIK3CG, KIT, KITLG, SELP, SERPINC1, SERPINE1
32	cerebritis	18.9	PIK3CG, KITLG, VWF, SELP, SERPINC1, SERPINE1
33	ovarian cancer	17.0	PIK3CG, KIT, KITLG, VWF, SERPINC1, SERPINE1
34	thyroiditis	16.9	PICALM, PIK3CG, KIT, KITLG, VWF, SELP
35	cervicitis	16.4	PIK3CG, KIT, KITLG, VWF, SERPINC1, SERPINE1
36	leukemia	14.8	PICALM, PIK3CG, KIT, KITLG, VWF, SELP
37	hemorrhagic thrombocythemia	14.1	MPL, JAK2, CD177, THPO
38	acquired polycythemia	14.0	JAK2, EPO, EPOR
39	aggressive systemic mastocytosis	14.0	KIT, KITLG, IFNA2, STAT5A
40	sm-ahnmd	14.0	KIT, KITLG, JAK2, IFNA2, PDGFRA, PDGFRB
41	congenital amegakaryocytic thrombocytopenia	14.0	MPL, IL3, THPO
42	diamond-blackfan anemia	14.0	KITLG, JAK2, IL3, G6PD, THPO, EPO
43	carcinoma	14.0	PIK3CG, KIT, KITLG, VWF, SELP, SERPINC1
44	thrombocytopenia due to platelet alloimmunization	14.0	SELP, MPL, THPO
45	myeloproliferative disorder with eosinophilia	13.9	BCR, IFNA2, PDGFRB
46	mast cell neoplasm	13.9	KIT, KITLG, FLT3, IL3
47	merkel cell carcinoma	13.9	KIT, KITLG, IFNA2, PDGFRA, EPO, EPOR
48	hypereosinophilic syndrome	13.9	KIT, FIP1L1, IL3, PDGFRA, PDGFRB
49	chondroma	13.9	KIT, IDH1, IDH2, HMGA2, PDGFRA
50	mitral valve stenosis	13.9	SELP, PPBP, PF4

Clinical features from OMIM: 263300

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 anagrelide, anagrelide hydrochloride, busulfan, hydroxyurea, interferon alfa-2b, pipobroman, uracil mustard

MalaCards organs/tissues related to polycythemia vera:

²²

MGI Mouse Phenotypes related to polycythemia vera:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.6	SOCS2, PTPN6, CBFB, ITGB3, SELP
2	endocrine/exocrine gland phenotype	MP:0005379	10.4	RXRB, PTPN6, PTS, HMGA2, ETV6
3	craniofacial phenotype	MP:0005382	9.9	CSF2, PDGFRB, PDGFRA, RXRB, PTPN9, HMGA2
4	renal/urinary system phenotype	MP:0005367	9.5	SOCS2, PRKG1, PDGFRB, PDGFRA, PTGS1, TET2
5	liver/biliary system phenotype	MP:0005370	9.4	IL6, IGFBP1, CBFB, TET2, RXRB, ABL1
6	other phenotype	MP:0005395	9.4	CSF2, STAT3, PDGFRA, PTGS1, ITGB3, JAK2
7	limbs/digits/tail phenotype	MP:0005371	9.1	SRC, CRABP2, PDGFRA, HFE, STAT1, SOCS2
8	embryogenesis phenotype	MP:0005380	8.6	SRC, RXRB, PDGFRA, ABL1, G6PD, SOCS3
9	hematopoietic system phenotype	MP:0005397	8.4	PICALM, ETV6, TET2, PTPN6, PTPN9, PDGFRA
10	reproductive system phenotype	MP:0005389	8.4	PDGFRA, TIMP1, STAT3, STAT5A, PRKG1, PRM2
11	digestive/alimentary phenotype	MP:0005381	8.3	PTGS1, PTPN6, PDGFRA, PDGFRB, ABL1, HFE
12	vision/eye phenotype	MP:0005391	8.1	CBFB, SRC, RXRB, PDGFRB, ABL1, STAT3
13	adipose tissue phenotype	MP:0005375	7.7	STAT3, STAT5A, SOCS2, SOCS3, CSF2, ACE
14	nervous system phenotype	MP:0003631	7.6	PTPN6, PTPN9, SRC, RXRB, PDGFRA, ABL1
15	muscle phenotype	MP:0005369	7.5	PTGS1, PDGFRA, PDGFRB, ABL1, STAT3, STAT1
16	normal phenotype	MP:0002873	7.5	ABL1, HFE, THBD, STAT3, STAT5A, STAT1
17	skeleton phenotype	MP:0005390	7.4	HRAS, TNFRSF11B, PTPN6, SRC, ABL1, STAT3
18	integument phenotype	MP:0010771	7.2	F5, F3, F2, CBFB, ETV6, HRAS
19	tumorigenesis	MP:0002006	6.5	SRC, PTGS1, TET2, HRAS, PDGFRA, ACE
20	behavior/neurological phenotype	MP:0005386	6.4	EIF2S1, ABL1, PDGFRA, RXRB, SRC, ACE
21	immune system phenotype	MP:0005387	6.3	ETV6, ACP1, HFE, TYK2, STAT3, STAT5A
22	growth/size phenotype	MP:0005378	5.3	RARB, F3, CBFB, ETV6, HRAS, HMGA2
23	mortality/aging	MP:0010768	5.1	RARB, F3, F2, CBFB, ETV6, HRAS
24	cellular phenotype	MP:0005384	4.5	BCL2L1, FLT3, IL3, IL6, GP1BA, IGFBP1
25	cardiovascular system phenotype	MP:0005385	3.5	HGF, EPO, EPOR, CSF2, MPO, ITGB2
26	homeostasis/metabolism phenotype	MP:0005376	3.3	LAMA5, MPL, MPO, JAK2, CD79A, ITGA2

Articles related to polycythemia vera:

(show top 50)    (show all 214)

id	Title	Authors	Year	Affiliating Genes
1	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. (21712540)	Stein B.L.... Moliterno A.R.	2011	ASXL1
2	Inflammation and thrombosis in essential thrombocythe mia and polycythemia vera: different role of C-reactive protein and pentraxin 3 . (21173097)	Barbui T.... Rambaldi A.	2011	CRP, PTX3
3	Relationship between clotting activity and phosphatid ylserine expression on erythrocyte membranes in polycythemia vera patients with the JAK2 V617F mutation. (21539404)	Fujita H.... Nishimura S.	2011	JAK2
4	Phase 2 study of CEP-701, an orally available JAK2 in hibitor, in patients with primary or post-polycythemia vera/essential thrombocy themia myelofibrosis. (20008298)	Santos F.P.... Verstovsek S.	2010	JAK2
5	Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. (20194236)	Spivak J.L.	2010	JAK2, THPO, CSF3
6	Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera. (19965650)	Randi M.L.... Donella-Deana A.	2010	SRC, JAK2
7	Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. (19190168)	Seaman V.... Hoffman R.	2009	JAK2
8	Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. (19252176)	Schnittger S.... Haferlach T.	2009	JAK2
9	The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. (18482053)	Manshouri T.... Verstovsek S.	2008	JAK2
10	Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera? (18292125)	Ohyashiki K.... Ohyashiki J.H.	2008	JAK2
11	Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. (18429051)	Tefferi A.	2008	JAK2
12	Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. (18519514)	Ricksten A.... Andreasson B.	2008	JAK2
13	JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera. (18297539)	Rothlisberger B.... Heizmann M.	2008	JAK2
14	Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. (18068534)	Helias C.... Lessard M.	2008	JAK2, MLLT3, KDM4C
15	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. (18451307)	Landgren O.... BjAPrkholm M.	2008	BCR
16	JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice. (18854675)	Means R.T.	2008	JAK2
17	Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (17229651)	Finazzi G.... Barbui T.	2007	JAK2
18	T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation. (17713553)	Ishii T.... Xu M.	2007	CSF2, IL11
19	Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. (17920755)	Williams D.M.... Moliterno A.R.	2007	JAK2, MPL
20	Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera. (17597478)	Quintas-Cardama A.... Verstovsek S.	2007	IFNA1
21	Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. (17262192)	Hussein K.... Bock O.	2007	JAK2
22	Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. (17412890)	Wautier M.P.... Wautier J.L.	2007	JAK2, LAMA5
23	Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. (17256145)	Steimle C.... Pahl H.L.	2007	CD177
24	Expertise-based management in essential thrombocythem ia and polycythemia vera. (18032974)	Finazzi G.... Barbui T.	2007	IFNA1
25	Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. (16620973)	Rossi D.... Gaidano G.	2007	JAK2
26	A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. (17213018)	Larsen T.S.... Kerndrup G.B.	2007	JAK2
27	Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status. (17611562)	Ohyashiki K.... Ohyashiki J.H.	2007	JAK2
28	High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. (16709929)	Kiladjian J.J.... Fenaux P.	2006	IFNA2, IFNA1
29	Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. (16772604)	Scott L.M.... Green A.R.	2006	JAK2
30	Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. (16827884)	Thurmes P.J.... Steensma D.P.	2006	JAK2, EPO
31	Identification of c-Kit gene mutations in patients with polycythemia vera. (16460801)	Fontalba A.... Richard C.	2006	PDGFRB, KIT
32	A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. (16639737)	Samuelsson J.... Birgegard G.	2006	IFNA2, IFNA1, CD177
33	Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera. (15958702)	Steidl U.... Kronenwett R.	2005	RARB, RXRB, CRABP2
34	Heparin-induced thrombocytopenia and thrombosis in a patient with polycythemia vera. (15335186)	Hayashi T.... Nomura T.	2004	PF4
35	Polycythemia vera and idiopathic erythrocytosis: comparison of clinical and laboratory parameters. (15270182)	Usman M.... Khurshid M.	2004	EPO
36	The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera. (15477215)	Johansson P.... Andreasson B.	2004	CD177
37	PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. (12920026)	Xu M.J.... Zhao Z.J.	2003	PTPN9
38	Gene expression profiling in polycythemia vera using cDNA microarray technology. (12873988)	Pellagatti A.... Boultwood J.	2003	CST7
39	Effect of diroton on characteristics of 24-hours art erial pressure monitoring in hypertensive patients with polycythemia vera (14520846)	Gorokhovskaia G.N.... Martynov A.I.	2003	ACE
40	Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. (10887148)	Tefferi A.... Li C.Y.	2000	MPL
41	End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis. (9647492)	SHIH L.Y.... Huang J.Y.	1998	EPO
42	The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. (9121771)	Asimakopoulos F.A.... Green A.R.	1997	PTPN6, EPOR, EPO
43	Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. (9226165)	Sui X.... Zhao Z.	1997	ACP1
44	Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. (9160662)	Dai C.H.... Sawyer S.T.	1997	KITLG, ACP1, EPO
45	Role of interferon alpha-2a in the treatment of polycythemia vera. (7832194)	Foa P.... Maiolo A.T.	1995	IFNA2, IFNA1
46	Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. (7542500)	Mirza A.M.... Axelrad A.A.	1995	IGF1R, IGF1
47	Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. (7957805)	Papineschi F.... Spremolla G.	1994	IFNA2
48	Polycythemia vera. (1587207)	Murphy S.	1992	EPO
49	Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure. (2069164)	Ohyashiki J.H.... Toyama K.	1991	EPO
50	Increased sensitivity of polycythemia vera blood burst-forming units-erythroid to interleukin 3. (2132535)	Dai C.H.... Gilbert H.S.	1990	IL3

Genes related to polycythemia vera according to GeneCards:

(show top 50)    (show all 99)

id	Symbol	Description	Score	GeneCards Section Context
1	CD177	CD177 molecule	11.0	Expressions, Publications, Functions
2	JAK2	Janus kinase 2	11.0	Publications
3	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
4	EPO	erythropoietin	11.0	Publications
5	EPOR	erythropoietin receptor	11.0	Publications
6	STAT5A	signal transducer and activator of transcription 5A	11.0	Publications
7	SOCS3	suppressor of cytokine signaling 3	11.0	Publications
8	THPO	thrombopoietin	11.0	Publications
9	PF4	platelet factor 4	11.0	Publications
10	ACP1	acid phosphatase 1, soluble	11.0	Publications
11	JAK1	Janus kinase 1	11.0	Publications
12	CSF3R	colony stimulating factor 3 receptor (granulocyte)	11.0	Publications
13	PTPN6	protein tyrosine phosphatase, non-receptor type 6	11.0	Publications
14	IFNA2	interferon, alpha 2	11.0	Publications
15	HMGA2	high mobility group AT-hook 2	11.0	Publications
16	TYK2	tyrosine kinase 2	11.0	Publications
17	PDGFRB	platelet-derived growth factor receptor, beta polypeptide	11.0	Publications
18	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)	11.0	Publications
19	THBD	thrombomodulin	11.0	Publications
20	IL3	interleukin 3 (colony-stimulating factor, multiple)	11.0	Publications
21	IFNA1	interferon, alpha 1	11.0	Publications
22	KITLG	KIT ligand	11.0	Publications
23	SELP	selectin P (granule membrane protein 140kDa, antigen CD62)	11.0	Publications
24	FLT3	fms-related tyrosine kinase 3	11.0
25	G6PD	glucose-6-phosphate dehydrogenase	11.0
26	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	11.0	Publications
27	STAT3	signal transducer and activator of transcription 3 (acute-phase response factor)	11.0	Publications
28	PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	11.0
29	IGF1R	insulin-like growth factor 1 receptor	11.0	Publications
30	TIMP1	TIMP metallopeptidase inhibitor 1	11.0	Publications
31	BCL2L1	BCL2-like 1	11.0	Publications
32	PRKG1	protein kinase, cGMP-dependent, type I	11.0
33	LUZP6	leucine zipper protein 6	11.0	UniProt Related
34	FAM215A	family with sequence similarity 215, member A (non-protein coding)	11.0	Publications
35	MPST	mercaptopyruvate sulfurtransferase	11.0	Publications
36	CST7	cystatin F (leukocystatin)	11.0	Publications
37	PRM2	protamine 2	11.0	Publications
38	PLVAP	plasmalemma vesicle associated protein	11.0	Publications
39	SOCS2	suppressor of cytokine signaling 2	11.0	Publications
40	PTX3	pentraxin 3, long	11.0	Publications
41	BOK	BCL2-related ovarian killer	11.0	Publications
42	TET2	tet methylcytosine dioxygenase 2	11.0	Publications
43	ACSL6	acyl-CoA synthetase long-chain family member 6	11.0	Publications
44	MMRN1	multimerin 1	11.0	Publications
45	CRABP2	cellular retinoic acid binding protein 2	11.0	Publications
46	HAMP	hepcidin antimicrobial peptide	11.0	Publications
47	PTPN9	protein tyrosine phosphatase, non-receptor type 9	11.0	Publications
48	IDH1	isocitrate dehydrogenase 1 (NADP+), soluble	11.0	Publications
49	IDH2	isocitrate dehydrogenase 2 (NADP+), mitochondrial	11.0	Publications
50	DPM1	dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit	11.0

Pathways related to polycythemia vera according to GeneDecks:

(show top 50)    (show all 187)

id	Pathway	Score	Top Affiliating Genes
1	Jak/Stat Pathway3	10.7	SOCS3, JAK1, JAK2, TYK2, STAT5A, SOCS2
2	Immune response Oncostatin M signaling via JAK-Stat in human cells10	10.6	STAT3, STAT5A, SOCS3, JAK2, JAK1, TIMP1
3	Immune response_Oncostatin M signaling via JAK-Stat in human cells41	10.4	SOCS3, JAK1, STAT1, STAT5A, TIMP1, JAK2
4	Development_EPO-induced Jak-STAT pathway41	10.2	EPOR, EPO, SOCS3, STAT1, STAT5A, STAT3
5	Jak-STAT signaling pathway20	10.2	SOCS2, CSF3R, EPO, EPOR, STAT1, JAK1
6	Actin-Based Motility by Rho Family GTPases36	10.2	ITGAM, IGF1, PPBP, THPO
7	Ras Pathway36	10.0	IL3, FLT3, ITGB3, ITGAM, ITGA2, KIT
8	Development_Thrombopoetin signaling via JAK-STAT pathway41	10.0	SOCS3, STAT5A, THPO, CRP, PTPN6, JAK2
9	Development EPO-induced Jak-STAT pathway10	10.0	SRC, PTPN6, HRAS, JAK2, BCL2L1, EPOR
10	Development_PDGF signaling via STATs and NF-kB41	9.8	PDGFRA, JAK2, JAK1, STAT1, STAT5A, STAT3
11	Development PDGF signaling via STATs and NF-kB10	9.8	STAT1, STAT5A, STAT3, PDGFRB, PDGFRA, HRAS
12	Development Thrombopoetin signaling via JAK-STAT pathway10	9.8	STAT3, CRP, PTPN6, JAK2, MPL, BCL2L1
13	Tyrosine Kinases / Adaptors3	9.8	ABL1, PDGFRB, PDGFRA, SRC, IGF1R, FLT3
14	Pathways in cancer20	9.4	RXRB, PDGFRA, ABL1, STAT3, STAT5A, CSF3R
15	PTEN Pathway36	9.4	PPBP, HRAS, THPO, PDGFRA, PDGFRB, HGF
16	14-3-3 Induced Intracellular Signaling36	9.4	PDGFRA, PDGFRB, TIMP1, THPO, EPOR, HRAS
17	ILK Signaling36	9.4	IGF1, PPBP, PDGFRA, PDGFRB, KIT, TIMP1
18	Glioma Invasiveness36	9.4	TIMP1, HGF, THPO, PPBP, IL3, ITGB2
19	ERK5 Signaling36	9.3	KIT, HGF, THPO, PDGFRB, PDGFRA, PPBP
20	Paxillin Interactions36	9.1	KIT, KITLG, ITGA2, EPOR, ITGAM, ITGB2
21	Hematopoietic cell lineage20	9.1	IL6, IL3, IL11, FLT3, ITGB3, ITGAM
22	Cytokine-cytokine receptor interaction20	9.1	EPO, IFNA1, IL6, IL3, IL11, FLT3
23	Blood Coagulation Signaling Pathways37	9.0	GP1BA, SERPINE1, SERPINC1, F5, PROC, PROS1
24	Endothelin-1 Signaling Pathway36	9.0	PDGFRA, KIT, FLT3, IL3, IL6, IGF1R
25	PPAR Pathway36	9.0	ITGA2, ITGAM, ITGB2, ITGB3, IL3, IL6
26	Nanog in Mammalian ESC Pluripotency36	8.9	KITLG, PPBP, PDGFRA, HRAS, IGF1, IGF1R
27	Nuclear Receptor Activation by Vitamin-A36	8.9	RXRB, CRABP2, PDGFRB, TIMP1, THPO, PDGFRA
28	Akt Signaling36	8.9	PIK3CG, KIT, ITGA2, ITGAM, ITGB2, EPOR
29	Pancreatic Adenocarcinoma36	8.7	SRC, PPBP, PDGFRA, PDGFRB, TIMP1, THPO
30	Signaling Involved in Cardiac Hypertrophy36	8.6	PDGFRB, STAT3, EPOR, ITGB2, ITGAM, JAK1
31	p70S6K Signaling36	8.6	IL3, IL6, IGF1R, IGF1, F2, THPO
32	eIF2 Pathway36	8.6	KIT, HGF, THPO, EIF2S1, PDGFRB, PDGFRA
33	GSK3 Signaling36	8.5	HGF, THPO, TIMP1, EIF2S1, PDGFRB, PDGFRA
34	Rac1 Pathway36	8.5	PDGFRB, TIMP1, THPO, HGF, PDGFRA, PPBP
35	Tec Kinases Signaling36	8.5	EPOR, HGF, CSF3R, STAT1, STAT5A, STAT3
36	STAT3 Pathway36	8.5	JAK2, HRAS, SRC, PF4, TYK2, STAT3
37	GPCR Pathway36	8.5	IL3, IL6, IGF1R, IGF1, HRAS, SRC
38	Rap1 Pathway36	8.4	EPOR, ITGAM, ITGB2, ITGB3, IL3, IL6
39	Molecular Mechanisms of Cancer36	8.3	IL6, IGF1R, HRAS, PPBP, PF4, PDGFRA
40	PAK Pathway36	8.3	THPO, HRAS, IL3, IGF1, KIT, IGF1R
41	Estrogen Pathway36	8.3	TIMP1, PDGFRB, PDGFRA, PPBP, HRAS, IGF1
42	JAK-STAT Pathway36	8.3	IGF1R, KIT, KITLG, MPL, JAK1, JAK2
43	Antioxidant Action of Vitamin-C36	8.3	IL11, PPBP, IL6, IL3, HGF, JAK2
44	UPA-UPAR Pathway36	8.3	ITGAM, STAT1, LAMA5, SERPINE1, JAK2, ITGA2
45	ERK Signaling36	8.3	CSF3, EPOR, PF4, IL3, SRC, HRAS
46	Renin-Angiotensin Pathway36	8.2	PPBP, HRAS, IGF1, PDGFRA, PDGFRB, ACE
47	Rho Family GTPases36	8.0	IL6, IGF1R, IGF1, PPBP, PF4, PDGFRA
48	Phospholipase-C Pathway36	7.8	LAMA5, KITLG, ITGAM, ITGA2, CD79A, KIT
49	p38 Signaling36	7.8	IL6, PDGFRB, TIMP1, THPO, STAT1, CSF2
50	MAPK Signaling36	7.7	IGF1, HRAS, SRC, PPBP, PDGFRA, PDGFRB

Compounds related to polycythemia vera according to GeneDecks:

(show top 50)    (show all 439)

id	Compound	Score	Top Affiliating Genes
1	cyclophosphamide32 34 9 9	13.4	ITGB2, LTF
2	threonine32	10.4	MPL, FLT3, GP1BA, IGFBP1, PTS, STAT1
3	citrate32	10.2	SELP, CD79A, CDKN3, PPBP, PF4, LTF
4	ag-129632	10.0	PIK3CG, KIT, KITLG, BCL2L1, FLT3, IL3
5	etoposide32 42 9 9	12.9	PIK3CG, BCL2L1, CDKN3, FLT3, IL3, IGF1R
6	methylcellulose32	9.9	KIT, KITLG, FLT3, IL11, IL3, IL6
7	dmso32	9.8	KITLG, SELP, ITGAM, F3, PTGS1, PPBP
8	polyethylene glycol32	9.6	KITLG, SERPINC1, MPL, MPO, IGFBP1, IFNA2
9	rapamycin32 42	10.6	PIK3CG, KIT, KITLG, JAK2, IGF1R, HRAS
10	hydroxyurea32 9 9	11.6	KIT, KITLG, JAK2, IL3, IFNA1, IFNA2
11	pge232	9.5	IGF1R, TNFRSF11B, PTGS1, PPBP, PF4, LTF
12	ristocetin32	9.4	VWF, SELP, SERPINC1, GP1BA, F2, SRC
13	ifn-alpha32	9.3	JAK1, IL6, IFNA1, IFNA2, HLA-G, TYK2
14	cytarabine32 34 9 9	12.2	KIT, KITLG, BCL2L1, BCR, MPO, FLT3
15	5-aza-2deoxycytidine32	9.2	KITLG, RARB, JAK2, ITGAM, FLT3, IL3
16	epinephrine32 9 18 9	12.0	KITLG, SELP, JAK2, CD79A, ITGA2, ITGAM
17	aprotinin32 9 9	11.0	VWF, SELP, SERPINC1, GP1BA, IGF1, F5
18	gm-csf32	8.9	KITLG, BCL2L1, IL11, IL3, IL6, PTGS1
19	doxorubicin32 34 9 9	11.9	PIK3CG, KIT, KITLG, BCL2L1, FLT3, IL11
20	h2o232	8.9	PIK3CG, KITLG, VWF, BCR, MPO, JAK1
21	warfarin32 34 9 18 9	12.8	VWF, SELP, SERPINC1, CD79A, F5, F3
22	oligonucleotide32	8.6	KIT, VWF, RARB, BCL2L1, BCR, JAK2
23	rantes32	8.6	KITLG, SELP, ITGAM, ITGB2, IL11, IL3
24	testosterone32 9 18 9	11.6	KIT, KITLG, SERPINC1, RARB, CD79A, IL3
25	desmopressin32 42 9 9	11.5	VWF, SELP, SERPINC1, SERPINE1, GP1BA, F5
26	arachidonic acid32 9 18 9	11.5	KITLG, VWF, SELP, BCL2L1, JAK2, ITGA2
27	superoxide32 18	9.2	KITLG, MPO, ITGAM, ITGB2, IGF1R, IFNA2
28	cysteine32	8.1	SELP, RARB, BCL2L1, MPL, MPST, CD79A
29	imatinib32 34 9 9	11.1	PIK3CG, KIT, KITLG, BCL2L1, BCR, JAK2
30	cyclosporin a32 42	8.9	PIK3CG, KITLG, VWF, SELP, JAK2, CDKN3
31	kininogen32	7.9	VWF, SELP, SERPINC1, SERPINE1, MPO, ITGB2
32	herbimycin a32 42	8.6	PIK3CG, KITLG, JAK2, CDKN3, ITGB2, FLT3
33	thymidine32 18	8.5	KIT, KITLG, BOK, RARB, BCR, JAK1
34	pd 98,05932	7.4	PIK3CG, KIT, KITLG, SERPINE1, BCL2L1, BCR
35	indomethacin32 9 9	9.3	MPO, JAK2, CD79A, CDKN3, ITGAM, ITGB2
36	ly29400232	7.3	PIK3CG, BCR, CDKN3, ITGAM, ITGB2, IL6
37	prednisolone32 9 9	9.2	KITLG, VWF, MPO, CD79A, CDKN3, ITGAM
38	phosphatidylinositol32	7.0	PIK3CG, KIT, KITLG, BCL2L1, BCR, MPL
39	prostacyclin32	7.0	VWF, SELP, SERPINC1, SERPINE1, IL3, GP1BA
40	heparin32 9 18 9	9.9	PIK3CG, KITLG, VWF, SERPINE1, LAMA5, MPO
41	actinomycin d32	6.9	PIK3CG, KIT, KITLG, SERPINE1, RARB, BCL2L1
42	fibrinogen32	6.8	SELP, SERPINC1, SERPINE1, CD79A, ITGA2, ITGAM
43	lactate32	6.3	KIT, KITLG, VWF, SELP, MPO, CD79A
44	creatinine32	6.0	KITLG, VWF, SELP, SERPINC1, MPO, CD79A
45	aspirin32 34 18	7.6	KITLG, VWF, SELP, SERPINC1, SERPINE1, MPL
46	alanine32	5.5	KITLG, VWF, SERPINC1, MPL, JAK1, JAK2
47	cycloheximide32	5.0	PIK3CG, KIT, KITLG, SERPINE1, RARB, BCL2L1
48	tyrosine32	4.9	PIK3CG, KIT, KITLG, VWF, SELP, RARB
49	serine32	4.6	PIK3CG, KIT, KITLG, VWF, SERPINC1, SERPINE1
50	vegf32	3.6	PIK3CG, KIT, KITLG, VWF, SELP, SERPINC1

Cellular components related to polycythemia vera according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	integrin complex	GO:008305	9.6	ITGB3, ITGB2, ITGAM, ITGA2
2	platelet alpha granule lumen	GO:031093	8.6	HGF, PROS1, TIMP1, PF4, PPBP, F5
3	plasma membrane	GO:005886	5.7	F2, HRAS, HLA-G, PTGS1, SRC, PDGFRA
4	extracellular region	GO:005576	5.5	PROS1, TIMP1, LTF, PF4, CRP, PPBP
5	extracellular space	GO:005615	4.8	EPO, F2, TNFRSF11B, PPBP, CRP, PF4

Biological processes related to polycythemia vera according to GeneDecks:

(show all 42)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of phospholipase C activity	GO:010863	10.7	PDGFRB, PDGFRA, KIT
2	regulation of interferon-gamma-mediated signaling pathway	GO:060334	10.6	SOCS3, STAT1, PTPN6, JAK2, JAK1
3	growth hormone receptor signaling pathway	GO:060396	10.6	JAK2, STAT3, SOCS2
4	regulation of type I interferon-mediated signaling pathway	GO:060338	10.6	SOCS3, STAT1, TYK2, PTPN6, IFNA2, JAK1
5	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.6	PDGFRB, PDGFRA, FLT3, KIT
6	JAK-STAT cascade involved in growth hormone signaling pathway	GO:060397	10.6	SOCS3, SOCS2, STAT1, STAT5A, STAT3, PTPN6
7	JAK-STAT cascade	GO:007259	10.6	SOCS3, SOCS2, STAT1, STAT5A, STAT3, JAK2
8	response to lipopolysaccharide	GO:032496	10.6	EPO, SOCS3, THPO, THBD, F3, JAK2
9	protein autophosphorylation	GO:046777	10.5	EIF2S1, PDGFRB, PDGFRA, IGF1R, FLT3, JAK2
10	type I interferon-mediated signaling pathway	GO:060337	10.5	SOCS3, STAT1, TYK2, PTPN6, HLA-G, IFNA2
11	interferon-gamma-mediated signaling pathway	GO:060333	10.5	SOCS3, STAT1, PTPN6, HLA-G, JAK2, JAK1
12	cell chemotaxis	GO:060326	10.4	HGF, PDGFRB, PDGFRA, KIT
13	negative regulation of platelet activation	GO:010544	10.2	THBD, PDGFRA, F2
14	peptidyl-tyrosine phosphorylation	GO:018108	10.2	STAT5A, ABL1, PDGFRB, PDGFRA, SRC, PTPN6
15	positive regulation of tyrosine phosphorylation of Stat5 protein	GO:042523	10.2	EPO, CSF2, IGF1, IL3, JAK2, KIT
16	cell proliferation	GO:008283	10.2	STAT3, THPO, PTPN6, HRAS, MPL, LAMA5
17	positive regulation of survival gene product expression	GO:045885	10.2	STAT5A, IL3, CSF2
18	aging	GO:007568	10.2	EPO, SOCS3, SOCS2, TIMP1, PTGS1, F3
19	erythrocyte maturation	GO:043249	10.1	EPO, TIMP1, G6PD
20	integrin-mediated signaling pathway	GO:007229	10.0	ITGB3, ITGB2, ITGAM, ITGA2, LAMA5
21	peptidyl-glutamic acid carboxylation	GO:017187	10.0	PROC, PROS1, F2
22	negative regulation of release of cytochrome c from mitochondria	GO:090201	9.9	HGF, IGF1, BCL2L1
23	positive regulation of DNA replication	GO:045740	9.9	EPO, CSF2, PDGFRA, HRAS, IGF1, IGF1R
24	fibrinolysis	GO:042730	9.8	PROS1, F2, GP1BA, SERPINE1
25	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.7	HGF, PDGFRB, PDGFRA, PTPN6, F2, IGF1
26	negative regulation of fibrinolysis	GO:051918	9.7	SERPINE1, F2, THBD
27	anti-apoptosis	GO:006916	9.6	EPO, HGF, SOCS3, SOCS2, F3, IGF1
28	cytokine-mediated signaling pathway	GO:019221	9.5	TYK2, STAT3, STAT5A, STAT1, SOCS3, CSF3
29	immune response	GO:006955	9.5	HAMP, CST7, CSF3, CSF2, HFE, PF4
30	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.5	HGF, IGF1, IL6, IL3, IL11, ITGB3
31	negative regulation of lipid storage	GO:010888	9.4	CRP, IL6, ITGB3
32	positive regulation of MAPK cascade	GO:043410	9.3	HRAS, IGF1, IGFBP3, IL6, IL11, FLT3
33	leukocyte migration	GO:050900	9.2	PTPN6, SRC, THBD, PROS1, PROC, HRAS
34	negative regulation of apoptotic process	GO:043066	9.2	EPO, CSF2, PROC, TIMP1, PF4, HMGA2
35	cell adhesion	GO:007155	9.1	GP1BA, F5, SRC, ABL1, CSF3R, MMRN1
36	platelet degranulation	GO:002576	9.0	HGF, PROS1, TIMP1, PF4, PPBP, F5
37	signal transduction	GO:007165	8.9	SRC, CRABP2, PDGFRB, STAT3, PRKG1, CSF3R
38	acute-phase response	GO:006953	8.8	STAT3, CRP, F2, IL6
39	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.3	STAT1, STAT5A, STAT3, RXRB, HMGA2, HRAS
40	positive regulation of cell proliferation	GO:008284	8.2	EPO, CSF3, CSF2, THPO, TIMP1, PDGFRB
41	platelet activation	GO:030168	7.4	HGF, PIK3CG, VWF, SELP, PROS1, THPO
42	blood coagulation	GO:007596	6.4	PIK3CG, F5, IFNA2, IGF1, GP1BA, MMRN1

Molecular functions related to polycythemia vera according to GeneDecks:

(show all 9)

id	Name	GO ID	Score	Top Affiliating Genes
1	growth hormone receptor binding	GO:005131	10.5	SOCS2, TYK2, JAK2, JAK1
2	vascular endothelial growth factor-activated receptor activity	GO:005021	10.4	FLT3, PDGFRA, PDGFRB
3	non-membrane spanning protein tyrosine kinase activity	GO:004715	9.9	TYK2, ABL1, SRC, JAK2, JAK1
4	protein tyrosine kinase activity	GO:004713	9.8	TYK2, ABL1, PDGFRB, SRC, IGF1R, JAK2
5	protease binding	GO:002020	9.3	F3, SERPINE1, SERPINC1, KIT
6	cytokine activity	GO:005125	9.2	CSF3, CSF2, THPO, TNFRSF11B, IFNA2, IL6
7	protein homodimerization activity	GO:042803	8.7	STAT1, G6PD, ACSL6, PDGFRA, PLVAP, CRP
8	growth factor activity	GO:008083	8.3	HGF, CSF3, CSF2, THPO, PPBP, F2
9	protein binding	GO:005515	2.7	EPOR, EIF2S1, ABL1, LTF, PDGFRB, PDGFRA